ELDN Stock Analysis: Buy, Sell, or Hold?
ELDN - Eledon Pharmaceuticals, Inc. Common Stock
$3.49
-0.04 (-1.13%)
▼
5d:
-10.51%
30d:
-7.67%
90d:
+39.04%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When ELDN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ELDN is down 10.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ELDN is down 10.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ELDN is currently trading at $3.49, which is considered oversold relative to its 30-day fair value range of $3.58 to $3.91.
Technical Outlook: Technically, ELDN is showing support break momentum. The price is currently testing key support at $3.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.20 (+135.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ELDN is showing support break momentum. The price is currently testing key support at $3.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.20 (+135.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.58 -
$3.91
Company Quality Score
51/100
(HOLD)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 16th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 135.0% below Wall St target ($8.20)
- WARNING: Recommendation downgraded due to -10.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.58 -
$3.91
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.46
(13.3%)
Support & Resistance Levels
Support Level
$3.43
Resistance Level
$4.04
Current Trend
Support Break
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.83
Wall Street Target
$8.20
(+135.0%)
Share & Embed Analysis
Last updated: June 03, 2026 8:50 PM ET
Data refreshes hourly during market hours. Next update: 9:50 PM
Data refreshes hourly during market hours. Next update: 9:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELDN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 55 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 55 HOLD |
